#

Pharmaceutical Companies

: 92
Novo Nordisk announced price cuts for flagship drugs in the US amid failed trials of a new weight loss product / Photo: KK Stock / Shutterstock
News·
Novo Nordisk to cut prices on weight loss products by up to 50%. Why is the stock falling?
Arcellx shares have soared on news of its acquisition / Photo: X / Nasdaq Exchange
Small Caps·
Cancer drugmaker Arcellx explodes 77% in a day as Gilead will acquire it
Morgan Stanley predicts AI will jeopardize 10% of jobs in the European banking sector.
Review·
I gave three AI chatbots €500 to invest. Here's what they did with my money
The failure of Novo Nordisks experimental drug trial collapsed the companys shares and pulled Danish markets / Photo: Tada Images / Shutterstock
News·
Novo's failure to test a weight loss drug has sparked a sell-off in the Danish market
Moderna shares rose after the regulator approved the mRNA vaccine application/Photo: Shutterstock.com/Inna Dodor
News·
A regulator in the US has had a dramatic change of heart on the new Moderna vaccine. Its shares rose 6%
US regulators have denied Modernas application for approval of a new flu vaccine / Photo: Shutterstock.com/Golden Shrimp
News·
Moderna's stock fell due to regulatory concerns. A more important development is also under attack
Novo Nordisk shares rise after rival company says it will stop selling Wegovy analog in the U.S. / Photo: Photo Nature Travel / Shutterstock
News·
Novo shares rise: cheap copy of its drug fails to survive criticism from US regulator
Eli Lilly forecasts revenue growth of 23-27% in 2026 / Photo: Tada Images/Shutterstock.com
News·
Eli Lilly predicted revenue growth of 27% in 2026. Why is it better than Novo Nordisk?
Novos revenue could fall 5-13% in 2026/ Photo: Kittyfly/ Shutterstock.com
News·
Novo Nordisk warned of a drop in revenue in 2026. Quotes collapsed by 15%
Pfizer has published the first results of studies on an obesity drug/ Photo: Pfizer.com
News·
Pfizer reveals data on obesity drug. Why are analysts and the market disappointed?
A generic price war could drop the cost of semaglutide in some countries to $15 for a monthly course / Photo: charlesdeluvio / Unsplash.com
Review·
Substance-for-money exchange: $32 billion semaglutide market enters patent collapse phase
Bayer expects to stop lawsuits from Americans against fertilizer producer Monsanto / Photo: Alfred Sonsalla / Shutterstock.com
News·
Bayer shares soared 7%. The company got a chance to get rid of thousands of lawsuits in the US
Load more